News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Mannheim Corporation Enrolls First Patient in Phase III Program for New Once-Daily Fixed-Dose Combination of Tiotropium Plus Olodaterol in COPD



9/21/2011 9:40:55 AM

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced enrolment has commenced in its TOviTO Phase III clinical trial program. It will investigate tiotropium plus olodaterol in a once-daily fixed-dose combination for the treatment of chronic obstructive pulmonary disease (COPD).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES